Jonathan Campbell

Abstract There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R–GIPR co-agonism is effective in the management of obesity and type 2 diabetes1,2, and lanifibranor—a nuclear-acting small-molecule triple agonist of PPARα, PPARγ and PPARδ—is in clinical phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis3.

Utah is remarkable. Year after year, we’re ranked as the strongest economy in the country. We have strong employment, fast-growing industries and a standard of living that draws families, businesses and investment from around the world. This success is no accident. It is the result of the vision and foundation laid by the generations who built this state. The challenge before us today is not finding opportunities for growth but ensuring we have the capacity to make the most of them.